Gamida Cell Ltd. (GMDA)
$2.2
Rating:
Recommendation:
-
| Symbol | GMDA |
|---|---|
| Price | $2.2 |
| Beta | 1.620 |
| Volume Avg. | 0.74M |
| Market Cap | 131.882M |
| Shares () | - |
| 52 Week Range | 2.1-6.84 |
| 1y Target Est | - |
| DCF Unlevered | GMDA DCF -> | |
|---|---|---|
| DCF Levered | GMDA LDCF -> | |
| ROE | -121.27% | Strong Sell |
| ROA | -49.10% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 398.47% | Strong Buy |
| P/E | - | |
| P/B | 5.24 | Strong Buy |
Latest GMDA news
About
Download (Excel)Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.